| P/E (FY) | — | Sales (TTM) | $1.06B |
| Earnings (TTM) | -$327.0M | ROE | −70.80% |
| Net Margin | −40.41% | ROIC | — |
| Debt / Equity | 3.60 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 17.12% |
Ionis Pharmaceuticals is a commercial-stage biotechnology company providing RNA-targeted medicines in the United States. Its marketed products include TRYNGOLZA for triglyceride reduction in familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, WAINUA and TEGSEDI for hereditary transthyretin amyloid polyneuropathy, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA. It is also developing Olezarsen in Phase 3 for hypertriglyceridemia and cardiovascular disease.
| Market Cap | $9.14B | Trading Days | 5292 |
| 52W High | 86.74 |
| 52W Low | 40.03 |
| % Off High | −36.25% |
| YTD | −30.10% | 1Y | 34.32% |
| 3Y | 38.98% | 5Y | 46.57% |
| 10Y | 91.75% | Since incept. (ann.) | 13.15% |
Ionis Operations 100%
| Ann. Volatility (1Y) | 53.16% | Ann. Volatility (3Y) | 44.14% |
| Sharpe (1Y) | 0.82 | Sharpe (3Y) | 0.49 |
| Max Drawdown (1Y) | −38.79% | Max Drawdown (3Y) | −52.36% |
| Beta (3Y, vs SPY) | 0.78 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NUVL | Nuvalent, Inc. | $9.01B | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| PTGX | Protagonist Therapeutics, Inc | $8.80B | — |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| CYTK | CYTOKINETICS INC | $9.89B | — |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| SMMT | Summit Therapeutics Inc. | $10.01B | — |
| CORT | CORCEPT THERAPEUTICS INC | $10.11B | 114.9 |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| GPCR | Structure Therapeutics Inc. | $10.21B |
| LQDA | Liquidia Corp | $7.72B | — |
